GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » EV-to-FCF

Firebrick Pharma (ASX:FRE) EV-to-FCF : -2.14 (As of Jun. 23, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Firebrick Pharma's Enterprise Value is A$9.83 Mil. Firebrick Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-4.60 Mil. Therefore, Firebrick Pharma's EV-to-FCF for today is -2.14.

The historical rank and industry rank for Firebrick Pharma's EV-to-FCF or its related term are showing as below:

ASX:FRE' s EV-to-FCF Range Over the Past 10 Years
Min: -12.37   Med: 0   Max: 0
Current: -2.14

ASX:FRE's EV-to-FCF is ranked worse than
100% of 535 companies
in the Drug Manufacturers industry
Industry Median: 22.83 vs ASX:FRE: -2.14

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-23), Firebrick Pharma's stock price is A$0.057. Firebrick Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.027. Therefore, Firebrick Pharma's PE Ratio for today is At Loss.


Firebrick Pharma EV-to-FCF Historical Data

The historical data trend for Firebrick Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma EV-to-FCF Chart

Firebrick Pharma Annual Data
Trend Jun21 Jun22 Jun23
EV-to-FCF
- -8.88 -4.32

Firebrick Pharma Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
EV-to-FCF -8.88 - -4.32 -

Competitive Comparison of Firebrick Pharma's EV-to-FCF

For the Drug Manufacturers - General subindustry, Firebrick Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Firebrick Pharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's EV-to-FCF falls into.



Firebrick Pharma EV-to-FCF Calculation

Firebrick Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=9.828/-4.603
=-2.14

Firebrick Pharma's current Enterprise Value is A$9.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Firebrick Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-4.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Firebrick Pharma  (ASX:FRE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Firebrick Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.057/-0.027
=At Loss

Firebrick Pharma's share price for today is A$0.057.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Firebrick Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.027.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Firebrick Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Firebrick Pharma (ASX:FRE) Business Description

Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of Nasodine, a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold.

Firebrick Pharma (ASX:FRE) Headlines

No Headlines